Nanotechnology solutions for Alzheimer's disease: Advances in research tools, diagnostic methods and therapeutic agents

Journal of Alzheimer's Disease

Volumn 13, Issue 2, 2008, Pages 199-223

  Nazem, Amir ^b   Mansoori, G Ali ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c 1120 Science and Engineering Offices   (United States)

Author keywords

Alzheimer's disease; Amyloid; Atomic force microscopy; Nanodiagnostics; Nanotechnology; Targeted drug delivery; Tau protein

Indexed keywords

1,2 DIOLEOYL SNGLYCERO 3 PHOSPHOETHANOLAMINE N [4 (4 MALEIMIDOPHENYL)BUTYRAMIDE]; ALPHA TOCOPHEROL; AMYLOID; AMYLOID BETA PROTEIN; CARBON NANOTUBE; CARBOXYFULLERENE; CYANOACRYLATE DERIVATIVE; DEFEROXAMINE; DENDRIMER; DONEPEZIL; ETHANOLAMINE DERIVATIVE; FULLERENE DERIVATIVE; GALANTAMINE; GOLD; GREEN FLUORESCENT PROTEIN; HYDROXYFULLERENE; MACROGOL; MALEIMIDE DERIVATIVE; MEMANTINE; NANOPARTICLE; PENICILLAMINE; POLY (BUTYL 2 CYANOACRYLATE); POLYSTYRENE; PULLULAN; PYRIDYLDITHIOPROPIONYLPHOSPHOETHANOLAMINE; QUANTUM DOT; RIVASTIGMINE; TACRINE; THIOFLAVINE; UNINDEXED DRUG; TAU PROTEIN;

ALZHEIMER DISEASE; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; CELL REGENERATION; DEGENERATIVE DISEASE; DIAGNOSTIC PROCEDURE; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MASS SPECTROMETRY; NANOTECHNOLOGY; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; HOSPITALIZATION; INSTRUMENTATION; METABOLISM; PATHOLOGY; RESEARCH; SENILE PLAQUE; STANDARD;

ALZHEIMER DISEASE; HUMANS; MICROSCOPY, ATOMIC FORCE; NANOTECHNOLOGY; RESEARCH; SENILE PLAQUES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 44849092655     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-13210     Document Type: Review

References (148)

1. J.L. Alonso and W.H. Goldmann, Feeling the forces: atomic force microscopy in cell biology, Life Sci 72(23) (25 Apr 2003), 2553-2560.
2. A. Alzheimer, Ueber eine eigenartige Erkrankung der Himrinde, Allg Z Psychiat Med 64 (1907), 146-148.
3. D.G. Anderson, S. Levenberg and R. Langer, Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells, Nat Biotechnol 22(7) (2004 Jul), 863-866. Epub 2004 Jun 13.
4. N. Andreasen and K. Blennow, CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clin Neurol Neurosurg 107(3) (Apr 2005), 165-173. Review.
5. M. Arimon, I. Diez-Perez, M.J. Kogan, N. Durany, E. Giralt, F. Sanz and X. Fernandez-Busquets, Fine structure study of Aβ1-42 fibrillogenesis with atomic force microscopy, FASEB J 19(10) (Aug 2005), 1344-1346. Epub 2005 May 26.
6. J. Avila, J.J. Lucas, M. Perez and F. Hernandez, Role of tau protein in both physiological and pathological conditions, Physiol Rev 84(2) (Apr 2004), 361-384. Review.
7. J. Benvenuto, Y. Jin, M. Casale, G. Lynch and R. Granger, Identification of diagnostic evoked response potential segments in Alzheimer's disease, Exp Neurol 176(2) (Aug 2002), 269-276.
8. T.L. Benzinger, D.M. Gregory, T.S. Burkoth, H. Miller-Auer, D.G. Lynn, R.E. Botto and S.C. Meredith, Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel betasheet with residues in exact register, Proc Natl Acad Sci USA 95(23) (10 Nov 1998), 1013407-1013412.
9. G. Bitan, M.D. Kirkitadze, A. Lomakin, S.S. Vollers, G.B. Benedek and D.B. Teplow, Amyloid β protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways, Proc Natl Acad Sci USA 100(1) (7 Jan 2003), 7330-7335.
10. G. Bitan, S.S. Vollers and D.P. Teplow, Elucidation of primary structure elements controlling Early Amyloid β-Protein Oligomerization, J Biol Chem 278(37) (12 Sep 2003), 34882-34889. Epub 2003 Jul 2.
11. H.K. Blackley, G.H. Sanders, M.C. Davies, C.J. Roberts, S.J. Tendler and M.J. Wilkinson, In-situ atomic force microscopy study of β-amyloid fibrillization, J Mol Biol 298(5) (19 May 2000), 833-840.
12. R.D. Brinton and J.M. Wang, Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent, Curr Alzheimer Res 3(3) (Jul 2006), 185-190.
13. A.D. Cash, G. Aliev, S.L. Siedlak, A. Nunomura, H. Fujioka, X. Zhu, A.K. Raina, H.V. Vinters, M. Tabaton, A.B. Johnson, M. Paula-Barbosa, J. Avíla, P.K. Jones, R.J. Castellani, M.A. Smith and G. Perry, Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation, Am J Pathol 162(5) (May 2003), 1623-1627.
14. C.L. Cheung, J.H. Hafner and C.M. Lieber, Carbon nanotube atomic force microscopy tips: Direct growth by chemical vapor deposition and application to high-resolution imaging, Proc Natl Acad Sci USA 97(8) (11 Apr 2000), 3809-3813.
15. M.S. Chong and S. Sahadevan, Preclinical Alzheimer's disease: diagnosis and prediction of progression, Lancet Neurol 4(9) (Sep 2005), 576-579. Review.
16. M. Citron, Alzheimer's disease: treatments in discovery and development, Nat Neurosci 5(Suppl) (Nov 2002), 1055-1057.
17. J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe and K.H. Ashe, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function, Nat Neurosci 8(1) (Jan 2005), 79-84.
18. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol Aging 20(2) (Mar-Apr 1999), 247.
19. C.F. Contreras, M.A. Canales, A. Alvarez, G.V. De Ferrari and N.C. Inestrosa, Molecular modeling of the amyloid-beta-peptide using the homology to a fragment of triosephosphate isomerase that forms amyloid in vitro, Protein Eng 12(11) (Nov 1999), 959-966.
20. Z. Cui, P.R. Lockman, C.S. Atwood, C.H. Hsu, A. Gupte, D.D. Allen and R.J. Mumper, Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases, Eur J Pharm Biopharm 59(2) (Feb 2005), 263-272.
21. D.R. Davis, B.H. Anderton, J.P. Brion, C.H. Reynolds and D.P. Hanger, Oxidative stress induces dephosphorylation of tau in rat brain primary neuronal cultures, J Neurochem 68(4) (Apr 1997), 1590-1597.
22. D.W. Dickson, Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 114(1) (Jul 2004), 23-27. Review.
23. K.E. Drexler, Molecular engineering: An approach to the development of general capabilities for molecular manipulation, Proc Natd Acad Sci USA 78(9) (Sep 1981), 5275-5278.
24. B. Dubertret, P. Skourides, D.J. Norris, V. Noireaux, A.H. Brivanlou and A. Libchaber, In vivo imaging of quantum dots encapsulated in phospholipid micelles, Science 298(5599) (29 Nov 2002), 1759-1762.
25. L.L. Dugan, J.K. Gabrielsen, S.P. Yu, T.S. Lin and D.W. Choi, Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons, Neurobiol Dis 3 (1996), 129-135.
26. L.L. Dugan, E.G. Lovett, K.L. Quick, J. Lotharius and T.T. Lin, O'Malley KL. Fullerene-based antioxidants and neurodegenerative disorders, Parkinsonism Relat Disord 7 (2001), 243-246.
27. L.L. Dugan, D.M. Turetsky, C. Du, D. Lobner, M. Wheeler, C.R. Almli, C.K. Shen, T.Y. Luh, D.W. Choi and T.S. Lin, Carboxyfullerenes as neuroprotective agents, Proc Natl Acad Sci USA 94(17) (19 Aug 1997), 9434-9439.
28. R.G. Ellis-Behnke, Y.X. Liang, S.W. You, D.K. Tay, S. Zhang, K.F. So and G.E. Schneider, Nano neuro knitting: Peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision, Proc Natl Acad Sci USA 103(13) (28 Mar 2006), 5054-5059. Epub 2006 Mar 20.
29. A. Engel and D.J. Muller, Observing single biomolecules at work with the atomic force microscope, Nat Struct Biol 7(9) (Sep 2000), 715-718.
30. M.J. Esplandiu, Scanning probe microscopies for analytical studies at the nanometer scale, Contrib Sci 3(1) (2005), 33-46.
31. C. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie and Y. Huang, Global prevalence of dementia: a Delphi consensus study, The Lancet 366(9503) (2005), 2112-2117.
32. R.P. Feynman, Eng Sci (Cal Tech) 23 22 (1960), http://www.zyvex.com/nanotech/feynman.html.
33. E.A. Fradinger and G. Bitan, En route to early diagnosis of Alzheimer's disease - are we there yet, Trends Biotechnol 23(11) (Nov 2005), 531-533.
34. X. Gao, L. Yang, J.A. Petros, F.F. Marshall, J.W. Simons and S. Nie, In vivo molecular and cellular imaging with quantum dots, Curr Opin Biotechnol 16(1) (Feb 2005), 63-72. Review.
35. S. Gauthier, N. Herrmann, F. Ferreri and C. Agbokou, Use of memantine to treat Alzheimer's disease, CMAJ 175(7) (26 Sep 2006), 777.
36. D.G. Georganopoulou, L. Chang, J.M. Nam, C.S. Thaxton, E.J. Mufson, W.L. Klein and C.A. Mirkin, Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proc Natl Acad Sci USA 102(7) (15 Feb 2005), 2273-2276.
37. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft and W.L. Klein, Alzheimer's disease-affected brain: Presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proc Natl Acad Sci USA 100(18) (2 Sep 2003), 10417-10422.
38. C.X. Gong, F. Liu, I. Grundke-Iqbal and K. Iqbal, Dysregulation of τ-protein phosphorylation/dephosphorylation in Alzheimer's disease: A therapeutic target, J Biomed Biotechnol (3) (2006), 318-325.
39. H. Grossman, C. Bergmann and S. Parker, Dementia: a brief review, Mt Sinai J Med 73(7) (Nov 2006), 985-992.
40. C. Ha and C.B. Park, Ex situ atomic force microscopy analysis of beta-amyloid self-assembly and deposition on a synthetic template, Langmuir 22(16) (1 Aug 2006), 6977-6985.
41. A.J. Haes, L. Chang, W.L. Klein and R.P. Van Duyne, Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor, J Am Chem Soc 127(7) (23 Feb 2005), 2264-2271.
42. A.J. Haes and R.P. Van Duyne, A nanoscale optical biosensor: sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles, J Am Chem Soc 124(35) (4 Sep 2002), 10596-10604.
43. B. Halliwell and J.M.C. Gutteridge, Free Radicals in Biology and Medicine, Oxford university press, New York, 2007.
44. P.K. Hansma, V.B. Elings, O. Marti and C.E. Bracker, Scanning tunneling microscopy and atomic force microscopy: application to biology and technology, Science 242(4876) (14 Oct 1988), 4209-4216, Review.
45. J. Hardy and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297(5580) (19 Jul 2002), 353-356.
46. J. Hardy, Toward Alzheimer therapies based on genetic knowledge, Annu Rev Med 55 (2004), 15-25.
47. J.D. Harper, S.S. Wong, C.M. Lieber and P.T. Lansbury, Jr., Assembly of Aβ Amyloid Protofibrils: An in vitro Model for a Possible Early Event in Alzheimer's Disease, Biochemistry 38(28) (13 Jul 1999), 8972-8980.
48. W. Hartig, B.R. Paulke, C. Varga, J. Seeger, T. Harkany and J. Kacza, Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting b-amyloid in Alzheimer's disease, Neurosci Lett 338(2) (27 Feb 2003), 174-176.
49. J.W. Hay and R.L. Ernst, The economic costs of Alzheimer's disease, Am J Public Health 77(9) (Sep 1987), 1169-1175.
50. H.M. Huang, H.C. Ou, S.J. Hsieh and L.Y. Chiang, Blockage of amyloid beta peptide-induced cytosolic free calcium by fullerenol-1, carboxylate C60 in PC12 cells, Life Sci 66(16) (2000), 1525-1533.
51. K. Ikeda, T. Okada, S. Sawada, K. Akiyoshi and K. Matsuzaki, Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones, FEBS Lett 580(28-29) (11 Dec 2006), 6587-6595.
52. M.D. Ikonomovic, D.M. Armstrong, S.H. Yen, C. Obcemea and B. Vidic, Atomic force microscopy of paired helical filaments isolated from the autopsied brains of patients with Alzheimer's disease and immunolabeled against microtubule-associated protein tau, Am J Pathol 147(2) (Aug 1995), 516-528.
53. M.C. Irizarry, Biomarkers of Alzheimer disease in plasma, NeuroRx 1(2) (Apr 2004), 226-234, Review.
54. K.K. Jain, Nanotechnology in clinical laboratory diagnostics, Clin Chim Acta 358(1-2) (Aug 2005), 37-54, Review.
55. K.K. Jain, The role of nanobiotechnology in drug discovery, Drug Discov Today 10(21) (11 Nov 2005), 435-442, Review.
56. K.K. Jain, Role of nanotechnology in developing new therapies for diseases of the nervous system, Nanomedicine 1(1) (2006), 9-12.
57. J.K. Jaiswal, H. Mattoussi, J.M. Mauro and S.M. Simon, Long-term multiple color imaging of live cells using quantum dot bioconjugates, Nat Biotechnol 21 (2003), 47-51.
58. C.D. Keating, Nanoscience enables ultrasensitive detection of Alzheimer's biomarker, Proc Natl Acad Sci USA 102(7) (15 Feb 2005), 2263-2264. Epub 2005 Feb 9.
59. J. Kelleher-Andersson, Discovery of Neurogenic, Alzheimer's Disease Therapeutics, Curr Alzheimer Res 3(1) (Feb 2006), 55-62.
60. A. Kinoshita, H. Fukumoto, T. Shah, C.M. Whelan, M.C. Irizarry and B.T. Hyman, Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes, J Cell Sci 116(Pt 16) (15 Aug 2003), 3339-3346.
61. B. Klajnert, M. Cortijo-Arellano, M. Bryszewska and J. Cladera, Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases, Biochem Biophys Res Commun 339(2) (13 Jan 2006), 577-582.
62. B. Klajnert, M. Cortijo-Arellano, J. Cladera and M. Bryszewska, Influence of dendrimer's structure on its activity against amyloid fibril formation, Biochem Biophys Res Commun 345(1) (23 Jun 2006), 21-28.
63. M.J. Kogan, N.G. Bastus, R. Amigo, D. Grillo-Bosch, E. Araya, A. Turiel, A. Labarta, E. Giralt and V.F. Puntes, Nanoparticle-mediated local and remote manipulation of protein aggregation, Nano Lett 6(1) (Jan 2006), 110-115.
64. Y.E. Koo, G.R. Reddy, M. Bhojani, R. Schneider, M.A. Philbert, A. Rehemtulla, B.D. Ross and R. Kopelman, Brain cancer diagnosis and therapy with nanoplatforms, Adv Drug Deliv Rev 58(14) (1 Dec 2006), 1556-1577.
65. T. Kowalewski and D.M. Holtzman, In situ atomic force microscopy study of Alzheimer's b-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation, Proc Natl Acad Sci USA 96 (March 1999), 3688-3693.
66. A.V. Kransnoslobodtsev, L.S. Shlyakhtenko, E. Ukraintsev, T.O. Zaikova, J.F. Keana and Y.L. Lyubchenko, Nanomedicine and protein misfolding diseases, Nanomedicine 1(4) (Dec 2005), 300-305.
67. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft and W.L. Klein, Diffusible, non-fibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins, Proc Natl Acad Sci USA 95(11) (26 May 1998), 6448-6453.
68. N.D. Lazo, M.A. Grant, M.C. Condron, A.C. Rigby and D.B. Teplow, On the nucleation of amyloid beta-protein monomer folding, Protein Sci 14(6) (Jun 2005), 1581-1596.
69. A.C. LeBlanc, The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death, Curr Alzheimer Res 2(4) (Oct 2005), 389-402.
70. H.G. Lee, P.I. Moreira, X. Zhu, M.A. Smith and G. Perry, Staying connected: Synapses in Alzheimer disease, Am J Pathol 165(5) (Nov 2004), 1461-1464.
71. P. Lewczuk, H. Esselmann, M. Otto, J.M. Maler, A.W. Henkel, M.K. Henkel, O. Eikenberg, C. Antz, W.R. Krause, U. Reulbach, J. Kornhuber and J. Wiltfang, Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ 42/Aβ 40 ratio and total tau, Neurobiol Aging 25(3) (Mar 2004), 273-281.
72. H. Lin, R. Bhatia and R. Lal, Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology, FASEB J 15(13) (Nov 2001), 2433-2444.
73. G. Liu, M.R. Garrett, P. Men, X. Zhu, G. Perry and M.A. Smith, Nanoparticle and other metal chelation therapeutics in Alzheimer disease, Biochim Biophys Acta 1741(3) (25 Sep 2005), 246-252.
74. G. Liu, P. Men, P.L. Harris, R.K. Rolston, G. Perry and M.A. Smith, Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance, Neurosci Lett 406(3) (9 Oct 2006), 189-193.
75. P.R. Lockman, R.J. Mumper, M.A. Khan and D.D. Allen, Nanoparticle technology for drug delivery across the blood brain barrier, Drug Dev Ind Pharm 28(1) (Jan 2002), 1-13.
76. M.A. Lovell and W.R. Markesbery, Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid, Arch Neurol 58 (2001), 392-396.
77. Y.L. Lyubchenko, S. Sherman, L.S. Shlyakhtenko and V.N. Uversky, Nanoimaging for protein misfolding and related diseases, J Cell Biochem 99(1) (1 Sep 2006), 52-70.
78. G.A. Mansoori, P. Mohazzabi, P. McCormack and S. Jabbari, Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead, WRSTSD 4(2/3) (2007), 226-257.
79. G.A. Mansoori, Principles of Nanotechnology- Molecular-Based Study of Condensed Matter in Small Systems, World Scientific Pub Co., 2005.
80. G.A. Mansoori, Advances in atomic & molecular nanotechnology, UN-APCTT Tech Monitor, 2002 Sep-Oct Special Issue: 53-59.
81. G.A. Mansoori and T.A. Fauzi Soelaiman, Nanotechnology - An introduction for the standards community, J ASTM Interntl 2(6) (Jun 2005).
82. G.A. Mansoori, Th.F. George, L. Assoufid and G. Zhang, Molecular Building Blocks for Nanotechnology, Springer, 2007.
83. C.L. Masters, R. Cappai, K.J. Barnham and V.L. Villemagne, Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics, J Neurochem 97(6) (Jun 2006), 1700-1725.
84. M.P. Mattson, Pathways towards and away from Alzheimer's disease, Nature 430 (2004), 631-639.
85. S.E. McNeil, Nanotechnology for the biologist, J Leukoc Biol 78(3) (Sep 2005), 585-594.
86. P.D. Meek, K. McKeithan and G.T. Schumock, Economic considerations in Alzheimer's disease, Pharmacotherapy 18(2 Pt 2) (Mar-Apr 1998), 68-73.
87. X. Michalet, F.F. Pinaud, L.A. Bentolila, S. Tsay, J.M. Doose, J.J. Li1, G. Sundaresan, A.M. Wu, S.S. Gambhir and S. Weiss, Quantum Dots for Live Cells, in vivo Imaging, and Diagnostics, Science 307(5709) (28 Jan 2005), 538-544.
88. F. Moreno-Herrero, M. Perez, A.M. Baro and J. Avila, Characterization by atomic force microscopy of Alzheimer paired helical filaments under physiological conditions, Biophys J 86(1 Pt1) (Jan 2004), 517-525.
89. F. Moreno-Herrero, J.M. Valpuesta, M. Perez, J. Colchero, A.M. Baro, J. Avila and E. Montejo De Garcini, Characterization by atomic force microscopy and cryoelectron microscopy of tau polymers assembled in Alzheimer's disease, J Alzheimers Dis 3(5) (Oct 2001), 443-451.
90. J.A. Mortimer, A.R. Borenstein, K.M. Gosche and D.A. Snowdon, Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression, J Geriatr Psychiatry Neurol 18(4) (Dec 2005), 218-223, Review.
91. D. Muller-Schultea and T. Schmitz-Rode, Thermosensitive magnetic polymer particles as contactless controllable drug carriers, J Magn Magn Mater 302(1) (2006), 267-271.
92. J.M. Nam, C.S. Thaxton and C.A. Mirkin, Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins, Science 301(5641) (26 Sep 2003), 1884-1886.
93. A. Nasehzadeh, A. Nikakhtar and G.A. Mansoori, Thermodynamic Treatment of DNA-Dendrimer Nano-Cluster System, Proceed. Int'l Congress of Nanotechnology (ICNT), San Francisco, CA, 2005. Oct. 31- Nov. 4,
94. P.J. Nestor, P. Scheltens and J.R. Hodges, Advances in the early detection of Alzheimer's disease, Nat Med 10(Suppl) (Jul 2004), S34-S41. Review.
95. T. Nishikawa, K. Akiyoshi and J. Sunamoto, Supramolecular assembly between nanoparticles of hydrophobized polysaccharide and soluble protein complexation between the self-aggregate of cholesterol-bearing pullulan and alpha-chymotrypsin, J Macromol 27 (1994), 7654-7659.
96. A. Nunomura, R.J. Castellani, X. Zhu, P.I. Moreira, G. Perry and M.A. Smith, Involvement of oxidative stress in Alzheimer disease, J Neuropathol Exp Neurol 65(7) (Jul 2006), 631-641.
97. W.M. Pardridge, Blood-brain barrier delivery, Drug Discov Today 12(1-2) (Jan 2007), 54-61.
98. P.N. Lacor, M.C. Buniel, L. Chang, S.J. Fernandez, Y. Gong, K.L. Viola, M.P. Lmbert, P.T. Velasco, E.H. Bigio, C.E. Finch, G.A. Krafft and L. William, Klein, Synaptic targeting by Alzheimer's-related amyloid β oligomers, J Neurosci 24(45) (10 Nov 2004), 10191-10200.
99. D. Patel, J. Henry and T. Good, Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers, Biochim Biophys Acta 1760(12) (Dec 2006), 1802-1809.
100. S. Pathak, E. Cao, M.C. Davidson, S. Jin and G.A. Silva, Quantum dot applications to neuroscience: new tools for probing neurons and glia, J Neurosci 26(7) (15 Feb 2006), 1893-1895.
101. J.R. Petrella, R.E. Coleman and P.M. Doraiswamy, Neuroimaging and early diagnosis of Alzheimer disease: a look to the future, Radiology 226(2) (Feb 2003), 315-336.
102. M.S. Pollanen, P. Markiewicz, C. Bergeron and M.C. Goh, Twisted ribbon structure of paired helical filaments revealed by atomic force microscopy, Am J Pathol 144(5) (May 1994), 869-873.
103. I.Y. Podolski, Z.A. Podlubnaya, E.A. Kosenko, E.A. Mugantseva, E.G. Makarova, L.G. Marsagishvili, M.D. Shpagina, Y.G. Kaminsky, G.V. Andrievsky and V.K. Klochkov, Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task, J Nanosci Nanotechnol 7(4-5) (Apr-May 2007), 1479-1485.
104. D. Purves, G.J. Augustine, D. Fitzpatrick, W.C. Hall, A.S. Lamantia, J.O. Mcnamara and S.M. Williams, Neuroscience, Sinauer Associates Inc., Sunderland, 2004.
105. C. Quintana, T.D. Wu, B. Delatour, M. Dhenain, J.L. Guerquin-Kern and A. Croisy, Morphological and chemical studies of pathological human and mice brain at the subcellular level: correlation between light, electron, and nanosims microscopies, Microsc Res Tech 70(4) (Apr 2007), 281-295.
106. H.H. Ramezani and G.A. Mansoori, Diamondoids as Molecular Building Blocks for Nanotechnology, in Molecular Building Blocks for Nanotechnology: From Diamondoids to Nanoscale Materials and Applications, Topics in Applied Physics 109, 44-71, Springer, New York, 2007
107. B. Reisberg, A. Doody R, Stöffler, F. Schmitt, S. Ferris and H.J. Möbius, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med 348 (31 Apr 2003), 333-341.
108. N. Relkin, Screening and early diagnosis of dementia, Am J Manag Care 6(22 Suppl) (Dec 2000), S1111-S1118; discussion S1119-S1124.
109. C. Roney, P. Kulkarni, V. Arora, P. Antich, F. Bonte, A. Wu, N.N. Mallikarjuana, S. Manohar, H.F. Liang, A.R. Kulkarni, H.W. Sung, M. Sairam and T.M. Aminabhavi, Targeted nanoparticles for drug delivery through the blood brain barrier for Alzheimer's disease, J Control Release 108(2-3) (28 Nov 2005), 193-214.
110. C. Roney, P. Kulkarni, V. Arora, M. Bennett, P. Antich et al., Polymeric Nanoparticulate Drug Delivery Through The Blood Brain Barrier, Polymer News 30(10) (Oct 2005).
111. M. Sano, Neuropsychological Testing in the Diagnosis of Dementia, J Geriatr Psychiatry Neurol 19(3) (Sep 2006), 155-159.
112. R.B. Sekar and A. Periasamy, Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations, J Cell Biol 160(5) (3 Mar 2003), 629-633.
113. D.J. Selkoe, Defining Molecular Targets to Prevent Alzheimer Disease, Arch Neurol 62(2) (Feb 2005), 192-195, Review.
114. D.J. Selkoe, Alzheimer disease: Mechanistic understanding predicts novel therapies, Ann Intern Med 140(8) (20 Apr 2004), 627-638.
115. D.J. Selkoe, Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases, Nat Cell Biol 6(11) (Nov 2004), 1054-1061.
116. D.J. Selkoe, Alzheimer's Disease: Genes, Proteins, and Therapy, Physiol Rev 81(2) (Apr 2001), 741-766, Review.
117. P.R. Selvin, The renaissance of fluorescence resonance energy transfer, Nat Struct Biol 7(9) (Sep 2000), 730-734.
118. T.B. Shea, D. Ortiz, R.J. Nicolosi, R. Kumar and A.C. Watterson, Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to Amyloid β, J Alzheimers Dis 7(4) (Aug 2005), 297-301.
119. J.P. Sheehan, R.H. Swerdlow, S.W. Miller, R.E. Davis, J.K. Parks, W.D. Parker and J.B. Tuttle, Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease, J Neurosci 17(12) (15 Jun 1997), 4612-4622.
120. Y. Shi, P.F. Stouten, N. Pillalamarri, L. Barile, R.V. Rosal, S. Teichberg, Z. Bu and D.J. Callaway, Quantitative determination of the topological propensities of amyloidogenic peptides, Biophys Chem 120(1) (1 Mar 2006), 55-61.
121. T. Shirahama and A.S. Cohen, High-resolution electron microscopic analysis of the amyloid fibril, J Cell Biol 33(3) (Jun 1967), 679-708.
122. M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione, S.G. Younkin et al., Production of the Alzheimer amyloid β protein by normal proteolytic processing, Science 258(5079) (2 Oct 1992), 126-129.
123. T. Siegemund, B.R. Paulke, H. Schmiedel, N. Bordag, A. Hoffmann, T. Harkany, H. Tanila, J. Kacza and W. Hartig, Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice, Int J Dev Neurosci 24(2-3) (Apr-May 2006), 195-201.
124. G.A. Silva, Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system, Surg Neurol 63(4) (Apr 2005), 301-306.
125. G.A. Silva, C. Czeisler, K.L. Niece, E. Beniash, D.A. Harrington, J.A. Kessler and S.I. Stupp, Selective differentiation of neural progenitor cells by highepitope density nanofibers, Science 303(5662) (27 Feb 2004), 1352-1355.
126. G.A. Silva, Neuroscience nanotechnology: progress, opportunities and challenges, Nat Rev Neurosci 7(1) (Jan 2006), 65-74.
127. P.D. Sloane, S. Zimmerman, C. Suchindran, P. Reed, L. Wang, M. Boustani and S. Sudha, The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances, Annu Rev Public Health 23 (2002), 213-231.
128. S.J. Son, X. Bai, A. Nan, H. Ghandehari and S.B. Lee, Template synthesis of multifunctional nanotubes for controlled release, J Control Release 114(2) (28 Aug 2006), 143-152.
129. K. Sugaya, A. Alvarez, A. Marutle, Y.D. Kwak and E. Choumkina, Stem cell strategies for Alzheimer's disease therapy, Panminerva Med 48(2) (Jun 2006), 87-96.
130. T. Sunderland, H. Hampel, M. Takeda, K.T. Putnam and R.M. Cohen, Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol 19(3) (Sep 2006), 172-179, Review.
131. J. Talafous, K.J. Marcinowski, G. Klopman and M.G. Zagorski, Solution structure of residues 1-28 of the amyloid betapeptide, Biochemistry 33(25) (28 Jun 1994), 7788-7796.
132. T.A. Taton, C.A. Mirkin and R.L. Letsinger, Scanometric DNA array detection with nanoparticle probes, Science 289(5485) (8 Sep 2000), 1757-1760.
133. C.E. Teunissen, J. de Vente, H.W. Steinbusch and C. De Bruijn, Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid, Neurobiol Aging 23(4) (Jul-Aug 2002), 485-508, Review.
134. H. Tohgi, T. Abe, K. Yamazaki, T. Murata, E. Ishizaki and C. Isobe, Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease, Neurosci Lett 269 (1999), 52-54.
135. J.D. Trobe and C.M. Butter, A screening test for integrative visual dysfunction in Alzheimer's disease, Arch Ophthalmol 111(6) (Jun 1993), 815-818.
136. V.N. Uversky, A.V. Kabanov and Y.L. Lyubchenko, Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi, J Proteome Res 5(10) (Oct 2006), 2505-2522, Review.
137. J.M. Van Kampen and C.B. Eckman, Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior, J Neurosci 26(27) (5 Jul 2006), 7272-7280.
138. S.V. Vinogradov, E.V. Batrakova and A.V. Kabanov, Nanogels for oligonucleotide delivery to the brain, Bioconjug Chem 15(1) (Jan-Feb 2004), 50-60.
139. D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan and D.J. Selkoe, Amyloid-β oligomers: their production, toxicity and therapeutic inhibition, Biochem Soc Trans 30(4) (Aug 2002), 552-557.
140. D.M. Walsh and D.J. Selkoe, Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease, Neuron 44(1) (30 Sep 2004), 181-193, Review.
141. Q. Wang, Y. Matsumoto, T. Shindo, K. Miyake, A. Shindo, M. Kawanishi, N. Kawai, T. Tamiya and S. Nagao, Neural stem cells transplantation in cortex in a mouse model of Alzheimer's disease, J Med Invest 53(1-2) (Feb 2006), 61-69.
142. S.S. Wong, J.D. Harper and P.T. Lansbury, Jr., Lieber CM, Carbon Nanotube Tips: High-Resolution Probes for Imaging Biological Systems, J Am Chem Soc 120 (1998), 603-604.
143. Y. Yoshiike, D.H. Chui, T. Akagi, N. Tanaka and A. Takashima, Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation, J Biol Chem 278(26) (27 Jun 2003), 23648-23655.
144. S. Yunxu, L. Danying, R. Yanfang, H. Dong and M. Wanyun, Three-dimensional structural changes in living hippocampal neurons imaged using magnetic AC mode atomic force microscopy, J Electron Microsc (Tokyo) 55(3) (Jun 2006), 165-172.
145. Y. Christen, Oxidative stress and Alzheimer disease, Am J Clin Nutr 71(Suppl) (2000), 621S-629S.
146. X. Zeng and M.S. Rao, Human embryonic stem cells: long term stability, absence of senescence and a potential cell source for neural replacement, Neuroscience 145(4) (14 Apr 2007), 1348-1358. Epub 2006 Oct 19.
147. M. Zimmermann, F. Gardoni and M. Di Luca, Molecular rationale for the pharmacological treatment of Alzheimer's disease, Drugs Aging 22(Suppl 1) (2005), 27-37.
148. http://www.nia.nih.gov/Alzheimers/Publications/UnravelingTheMystery/.